Current Progresses and Trends in the Development of Progesterone Receptor Modulators

Author(s): Wenlu Li, Xi Li, Bin Zhang, Chunmei Gao, Yuzong Chen, Yuyang Jiang

Journal Name: Current Medicinal Chemistry

Volume 23 , Issue 23 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer


The progesterone receptor (PR) is a ligand-activated steroid receptor in the nuclear receptor (NR) superfamily of transcription factor. Besides gynecological and obstetrical indications, the involvement/mechanism of PR in many other diseases, such as oncology, neurology, immunology, etc. has been revealed and studied in recent decades. Therapeutic agents that selectively activate or inhibit PR have been developed. PR agonists have generally been used in oral contraception and postmenopausal hormone replacement therapy (HRT), typically in combination with estrogens. PR antagonists and selective PR modulators (SPRMs) can be useful therapies for hormone dependent breast and prostate cancers, nonmalignant chronic conditions such as fibroids, and endometriosis. This review provides an overview and detailed discussions about the recent development of chemical structures of the PR ligands, their structural characteristics (particularly those contributing to their activity and selectivity), in vitro/in vivo studies and clinical trial outcomes, and the synthetic methodologies.

Keywords: Agonist, Antagonist, Ligand, Modulator, Nonsteroid, Progesterone receptor, Steroid.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 22 August, 2016
Page: [2507 - 2554]
Pages: 48
DOI: 10.2174/0929867323666160428105310
Price: $65

Article Metrics

PDF: 41